Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...

CAGR is driven by advancements in epigenetics research, methylation analysis technologies, and the rising need for ...

York-based biotech firm Aptamer Group has announced a licensing agreement with synthetic biology and genomics company Twist ...

The Vietnam Academy of Science and Technology (VAST) organised a ceremony in Hanoi on December 11 to announce DNA ...

A landmark study, titled “How error correction affects polymerase chain reaction deduplication: A survey based on unique molecular identifier datasets of short reads” recently published in ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, ...

The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...

DNAe, the Next-Generation Sequencing (NGS) company developing a transformative fully automated, sample-to-report diagnostics platform, today unveils a new Early Access Program, offering clinical ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Learn more about whether Aurinia Pharmaceuticals Inc. or Twist Bioscience Corporation is a better investment based on AAII's ...

Seq, a CRISPR-based method that enriches ultra-rare tumor DNA in blood by removing background wild-type DNA before sequencing ...